BY SEAN WHOOLEY
MassDevice — Day Zero Diagnostics announced that it received an award of up to $6.2 million in non-dilutive funding from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).
The funding from the non-profit partnership dedicated to accelerating early antibacterial R&D is intended to support Day Zero’s diagnostic system designed to help physicians diagnose and treat life-threatening bacterial infections.
Boston-based Day Zero said in a news release that its system helps offer the most effective antibiotic treatment on the first day that patients are admitted to the hospital, rather than having them undergo multiple days of toxic broad-spectrum antibiotics to prevent septic shock.